DUBLIN – French immunotherapy firm DBV Technologies SA put down a big marker by pricing biotech's largest secondary offering on Nasdaq so far this year, a hefty $244.8 million raise, which will further development of its peanut allergy therapy, which is entering pivotal trials later this year.